Profit lagging revenue
Revenue grew 10.9% but profit declined 74.2%, so the company kept less of each rupee of revenue as profit.
Importance 74 / 95 · growth
The strongest observations the engine found, ranked. Every line is generated from the filed numbers by a fixed rule — no opinion, no estimate.
Revenue grew 10.9% but profit declined 74.2%, so the company kept less of each rupee of revenue as profit.
Importance 74 / 95 · growth
EBITDA margin dropped 6.2 percentage points in a single year, from 28.7% to 22.4% — worth investigating.
Importance 70 / 95 · anomaly
ROCE has fallen for 6 consecutive years, from 13.6% to 3.8%.
Importance 69 / 95 · profitability
The P/E of 174.34× is above the pharmaceuticals median (45.29×) while profit declined 74.2% last year.
Importance 62 / 95 · valuation
Classified by the exchange under Healthcare › Healthcare › Pharmaceuticals & Biotechnology › Pharmaceuticals.
Peer set used on this page: 12 pharmaceuticals.
Revenue fell 2.9% a year over 7 years, from ₹2,885 cr in FY2019 to ₹2,346 cr in FY2026. Net profit fell 30.9% a year over the same period, including a one-off charge of ₹215 cr; excluding it, a profit of about ₹252 cr.
Revenue grew 10.9% but profit declined 74.2%, so the company kept less of each rupee of revenue as profit.
Rule PROFIT_SLOWER_THAN_REVENUE
Revenue grew 10.9% but EBITDA margin fell 6.2 percentage points to 22.4%, so the company kept less of each rupee of revenue as operating profit.
Profit has swung sharply over 7 years (from ₹369 to ₹1,429) — one year is a weak guide to the earnings power.
Revenue compounded at 17.4% a year over 7 years (₹5,514 → ₹16,927).
Net profit fell 74.2% year on year (FY2025 → FY2026).
In Q2 FY27 (Jul–Sep 2026), revenue was ₹4,389 cr (up 2.2% on the same quarter last year) and net profit ₹57 cr (down 57.3%).
Quarterly results, the trailing-twelve-months snapshot, and verified corporate actions — kept separate from each other and from the annual story above. Every figure traces to a filed number; nothing here is external news or commentary.
Q2 FY27 net profit was ₹57 cr, down 57.3% from ₹133 cr a year earlier.
Rule QTR_PROFIT_GROWTH_YOY
Q2 FY27 net profit declined 57.3% while revenue grew 2.2% vs the same quarter last year — a gap of 59.5 percentage points.
Rule QTR_PROFIT_VS_REVENUE_GROWTH
Q2 FY27 EBIT was ₹302 cr, down 33.8% from ₹455 cr a year earlier.
Rule QTR_OPERATING_PERFORMANCE_CHANGE_YOY
| Quarter | Revenue | YoY | Net profit | YoY | Net margin |
|---|---|---|---|---|---|
| Q3 FY25 | 3,821 | −3.3% | 81 | −89.2% | 2.1% |
| Q4 FY25 | 4,417 | +12.8% | 459 | +106.1% | 10.4% |
| Q1 FY26 | 3,942 | +14.8% | 89 | −89.6% | 2.3% |
| Q2 FY26 | 4,296 | +19.6% | 133 | +390.0% | 3.1% |
| Q3 FY26 | 4,173 | +9.2% | −52 | −163.9% | −1.2% |
| Q4 FY26 | 4,517 | +2.3% | 199 | −56.8% | 4.4% |
| Q1 FY27 | 4,336 | +10.0% | 137 | +53.4% | 3.2% |
| Q2 FY27 | 4,389 | +2.2% | 57 | −57.3% | 1.3% |
Trailing twelve months to 30 Sept 2026 · sum of the last 4 contiguous quarters
EBITDA margin was 23.3% in FY2026, against 17.4% in FY2019. ROE was 0.2% and ROCE 1.9% in FY2026.
ROCE has fallen for 6 consecutive years, from 13.6% to 3.8%.
Rule ROCE_DECLINING_STREAK
EBITDA margin of 22.4% is the thinnest in 7 years (prior range 25.8% to 28.7%).
ROE of 1.1% is below the pharmaceuticals median of 14.4%.
ROE of 1.1% is the lowest in 7 years (prior range 4.0% to 14.9%).
ROE declined from 5.4% to 1.1% year on year.
It had little or no debt in FY2026 (debt-to-equity 0.04x). Operating cash flow was -4.84x net profit.
Operating cash flow has matched or exceeded reported profit in 6 of the last 6 profit-making years (latest 5.41×).
Rule CFO_CONSISTENTLY_EXCEEDS_PAT
Net worth compounded at 27.4% a year over 7 years (₹6,707 → ₹36,622) — though FY2023 saw a one-off step-change of 137% (a merger, restructuring or a recovery off a low base), so the compounding is uneven.
Operating profit covers interest only 1.86× (FY2026).
Debt-to-equity fell from 0.64× to 0.40× year on year.
Within its 12-company Pharmaceuticals peer group, it ranks 12 of 12 on return on equity and 11 of 12 on EBITDA margin. P/E is not meaningful this year because FY2026 profit is driven by a one-off charge.
Ranked against 12 pharmaceuticals (FY2026, consolidated).
BIOCON · 9th of 12 · set median 14.8%
BIOCON · 11th of 12 · set median 28.7%
BIOCON · 12th of 12 · set median 14.4%
BIOCON · 12th of 12 · set median 45.3×
The P/E of 174.34× is above the pharmaceuticals median (45.29×) while profit declined 74.2% last year.
Rule PRICED_FOR_GROWTH
On the trailing twelve months. Last full year: P/E 160.9× · P/S 3.4× · ROE 1.1%.
The share price is down 7.4% over 1 year, up 56.6% over 3 years (16.1% a year) and down 0.3% over 5 years (−0.1% a year). These are price changes excluding dividends, adjusted for splits and bonuses, to 20 Nov 2026; it is 17.0% below its 52-week high.
Long-term price performance is shown above.
Price-action indicators as of 2026-11-20. Secondary to the fundamentals above — included for timing context, not as a signal.
Observations the engine tagged watch or deteriorating — prompts for your own research, not conclusions.
The full statements, kept deliberately secondary. Every figure traces to a BSE Integrated Filing (inline XBRL); ratios are recomputed from the normalised facts.
| Metric | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 2,885 | 1,988 | 2,028 | 1,738 | 1,993 | 2,127 | 2,243 | 2,346 |
| Total income | 3,002 | 2,190 | 2,179 | 1,925 | 2,264 | 2,320 | 2,485 | 2,666 |
| EBITDA | 503 | 488 | 463 | 248 | 295 | 456 | 418 | 546 |
| Profit before tax | 552 | 548 | 359 | 140 | 2,971 | 150 | 661 | 51 |
| Net profit | 493 | 441 | 281 | 86 | 2,848 | 119 | 609 | 37 |
| EPS (₹) | 8.3 | 3.7 | 2.4 | 0.7 | 23.9 | 1.0 | 5.1 | 0.3 |
| Net worth | 7,115 | 7,537 | 7,907 | 8,093 | 10,916 | 10,912 | 11,524 | 27,080 |
| Total debt | 1 | 1 | 0 | 76 | 1,298 | 2,041 | 2,871 | 1,150 |
| Operating cash flow | — | — | 571 | 48 | 219 | −123 | 621 | −180 |
| Free cash flow | — | — | 424 | −190 | −40 | −424 | 304 | −463 |
| Ratio | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|---|---|
| Growth | ||||||||
| Revenue growth YoY | — | -31.1 | 2.0 | -14.3 | 14.7 | 6.7 | 5.4 | 4.6 |
| Profit growth YoY | — | -10.5 | -36.4 | -69.3 | 3208.2 | -95.8 | 410.7 | -93.9 |
| Profitability | ||||||||
| EBITDA margin % | 17.4 | 24.5 | 22.8 | 14.3 | 14.8 | 21.4 | 18.6 | 23.3 |
| Net margin % | 16.4 | 20.1 | 12.9 | 4.5 | 125.8 | 5.1 | 24.5 | 1.4 |
| Return on equity % | 6.9 | 6.0 | 3.6 | 1.1 | 30.0 | 1.1 | 5.4 | 0.2 |
| Return on capital % | 5.0 | 5.3 | 4.7 | 1.7 | 1.7 | 2.7 | 2.1 | 1.9 |
| Leverage & cash | ||||||||
| Debt to equity | 0.00 | 0.00 | 0.00 | 0.01 | 0.12 | 0.19 | 0.25 | 0.04 |
| Cash flow ÷ profit | — | — | 2.04 | 0.55 | 0.08 | -1.03 | 1.02 | -4.84 |
| Current ratio | 2.46 | 2.86 | 3.94 | 4.07 | 3.68 | 3.99 | 1.25 | 1.16 |